By Kimberly Chin

 

Gilead Sciences Inc. raised the upper end of its full-year product sales target range, as the company saw a strong first half of the year for its products.

The biopharmaceutical company now expects total product sales between $24.4 billion and $25 billion, compared with its prior view of $23.7 billion to $25.1 billion.

Gilead expects sales of Veklury to be in the range of $2.7 billion to $3.1 billion, up from its previous projection of $2 billion to $3 billion, reflecting the longer than expected effect of the coronavirus pandemic on its HIV business, the company said. Veklury's sales tend to be affected by Covid-19-related rates of infections, hospitalizations and vaccinations.

On a GAAP basis, it expects full-year earnings around $4.70 to $5.05 a share, lower than its previous guidance of $4.75 to $5.45 a share. The company expects adjusted earnings around $6.90 to $7.25 a share, compared with its prior outlook of $6.75 to $7.45 a share.

Gilead's shares slipped 2.2% after hours to $68.30.

 

Write to Kimberly Chin at kimberly.chin@wsj.com

 

(END) Dow Jones Newswires

July 29, 2021 17:17 ET (21:17 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Gilead Sciences Charts.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Gilead Sciences Charts.